IQVIA二季度业绩超预期并上调2026年收入、EBITDA和调整后EPS指引

Earnings Call Insights: IQVIA (IQV) Q2 2026
Management view
- CEO & Chairman Ari Bousbib said, "IQVIA delivered an outstanding second quarter with revenue, adjusted EBITDA and adjusted diluted earnings per share, all exceeding the high end of our guidance," adding that "Organic growth for the company as a whole accelerated to 6% year-over-year" and that "Adjusted EBITDA margin began improving earlier than we had anticipated due to better operational performance."
- Bousbib highlighted R&D demand and conversion, saying, "We had $3.150 billion in net new bookings, representing 19% growth year-over-year, and 27% growth sequentially" and "a quarterly book-to-bill ratio of 1.22x," while also pointing to the longer-cycle trend: "With $11.3 billion of last 12-month net new bookings as of June 30, they are up 13% year-over-year."
- On Commercial Solutions, Bousbib said, "Organic revenue growth accelerated year-over-year to 5%," and added, "Analytics and Consulting grew organically high single digits year-over-year, the highest growth rate since 2022," while "Commercial engagement services and patient solutions, both continued to grow double digits year-over-year, and our AI offerings gained further traction with increased customer adoption."
- CFO Michael Fedock reported, "Second quarter revenue of $4.368 billion," "Second quarter adjusted EBITDA was $994 million," and "adjusted diluted earnings per share was $3.15," and said quarterly cash generation strengthened with "free cash flow of $360 million, representing growth of 23% year-over-year," alongside "we repurchased $398 million of our shares."
Outlook
- Fedock said, "we are raising our full year 2026 guidance for revenue, for adjusted EBITDA and for adjusted diluted earnings per share," and guided revenue to "$17.275 billion and $17.475 billion" and adjusted diluted EPS to "between $12.80 and $13."
- On quarterly cadence, Fedock provided Q3 guidance of revenue "between $4.315 billion and $4.390 billion" and adjusted diluted EPS "between $3.19 and $3.29," adding, "Both this guidance and the full year guidance assumes that foreign currency rates as of July '27 continue for the balance of the year."
- Versus Q1’s messaging, management’s guidance language shifted from "reaffirming our full year 2026 guidance for revenue and adjusted EBITDA" (Q1) to Q2’s explicit "raising" of revenue, adjusted EBITDA, and adjusted diluted EPS ranges.
Financial results
- Fedock said IQVIA’s Q2 segment revenue included "Commercial Solutions revenue for the second quarter was $1.793 billion" and "R&D Solutions second quarter revenue was $2.575 billion," and for bookings/backlog: "R&D Solutions net new bookings in the quarter were $3.15 billion" and "R&DS backlog was $34.2 billion."
- On profitability and below-the-line results, Fedock reported "Second quarter GAAP net income was $256 million, and GAAP diluted earnings per share was $1.53," alongside "Second quarter adjusted net income was $527 million."
- On balance sheet and leverage, Fedock said, "cash and cash equivalents were $1.909 billion," "net debt of $14.090 billion," and "Our net leverage ratio ended the quarter at 3.59x trailing 12 months adjusted EBITDA."
Q&A
- Eric Coldwell, Baird: asked if there were "any chunky awards" behind bookings strength and about "FSP awards" and "pass-through mix"; CEO Bousbib replied, "there is absolutely nothing salient, unusual, abnormal" and that "Pass-throughs were in the normal range, cancellations were in the normal range," adding "around FSP... low to mid-double digits kind of as usual percentage of total" (with CFO Fedock: "really nothing to call out there").
- Justin Bowers, Deutsche Bank: asked whether outsourcing penetration comments were broad-based; CEO Bousbib said, "the use of AI in Discovery will only increase demand for CRO services" and that some clients "are predicting they will double their study portfolio" and "asking us literally to ask thousands of FCEs in anticipation of those studies."
- Michael Ryskin, BofA: asked about AI solution development and incremental investment; CEO Bousbib said, "we now have 294 agents deployed across 90 use cases" and added, "4 of the top 10 pharma companies have already contracted with us to codevelop AI solutions" and "19 of the top 20 pharma companies have already deployed IQVIA solutions in their workflow."
- Michael Cherny, Leerink: asked about competitive displacement and the role of "price versus capabilities versus technology"; CEO Bousbib said, "it's less on price on a specific RFP and more on delivery time lines, capabilities, technology... and of course, our AI capabilities."
- David Windley, Jefferies: asked about acquisition contribution by segment and discovery investment; CFO Fedock said acquisition impact is "usually about 2/3 commercial, 1/3 R&DS," while CEO Bousbib added, "we completed the acquisition of the Charles River assets in the quarter" and on discovery buildout said, "yes, we are working on those things."
- Jailendra Singh, Truist: asked about faster-than-expected margin improvement and AI productivity; CFO Fedock said, "our operational and productivity programs are going exceptionally well" and "that drove about 90 basis points of operational margin expansion," with CEO Bousbib adding pass-throughs "created a headwind of 80 bps."
- Elizabeth Anderson, Evercore ISI: asked about guidance allocation and below-the-line changes; CFO Fedock said, "no significant changes on the below-the-line assumptions," and separately flagged backlog quality work: "if there is an adjustment to our backlog for inactive trials, it's in the ballpark of 5%" and "it will have 0 impact on any historical financial results, guidance, the next 12 months revenue from backlog."
Sentiment analysis
- Analysts’ tone was slightly positive and probing, with Baird’s Coldwell calling it "a pretty positive update" while still pressing on whether bookings included "chunky awards" and mix details.
- Management tone was positive and confident in execution and demand, with Bousbib stating, "I've never had as clean a quarter as this one all around," while also using clarifying language on backlog quality and policy: "we continue to have contracted bookings."
- Compared with Q1’s heavier focus on explaining the "book-to-bill ratio 1.04x" and "pass-through bookings were unusually low," Q2 sentiment read cleaner operationally and more centered on raised guidance and broad-based demand indicators.
Quarter-over-quarter comparison
- Guidance shifted from Q1’s "reaffirming" revenue/EBITDA (and only raising EPS) to Q2’s broad upward revisions: "raising our full year 2026 guidance for revenue, for adjusted EBITDA and for adjusted diluted earnings per share."
- Disclosures evolved from Q1’s detailed explanation of low pass-through bookings impacting book-to-bill to Q2’s emphasis that bookings strength was "literally across the board" with "nothing unusual."
- AI narrative stayed central, but Q2 added scaling and commercialization language ("294 agents deployed across 90 use cases") and tied AI more directly to demand and win rates, while Q1 emphasized the platform launch ("we unveiled IQVIA.ai") and early deployment counts.
Risks and concerns
- Management addressed potential investor concern around backlog quality, with Fedock saying inactive-trial adjustment work was underway and, if made, would be "in the ballpark of 5%" and "0 impact" on guidance or near-term backlog conversion.
- Margin headwinds were framed around pass-throughs and FX dynamics, with Bousbib stating, "The main headwind, nonoperational headwind, to margins is the pass-throughs, which, as you know, come with no profit."
Final takeaway
Management framed Q2 as a broad-based operational quarter with accelerating organic growth, stronger R&D bookings and backlog conversion indicators, and improving Commercial momentum tied to launch activity and expanding AI deployments. Leadership raised full-year 2026 guidance across revenue, adjusted EBITDA, and adjusted EPS, while using Q&A to emphasize that bookings strength was not driven by one-off awards and to preempt backlog-quality concerns by stating any inactive-trial adjustment would be limited and would not affect guidance or near-term backlog revenue conversion.
Read the full Earnings Call Transcript